IMA

ImageneBio, Inc. Common Stock
IMA

15.29 USD
+0.09
0.59%
At close Jul 30, 4:00 PM EDT
After hours
15.90
+0.61
3.99%
1 day
0.59%
5 days
-4.91%
1 month
-4.91%
3 months
0.33%
6 months
-14.49%
Year to date
-22.78%
1 year
-25.05%
5 years
-96.02%
10 years
-96.02%
Healthcare Biotechnology
0
Funds holding %
of 7,323 funds
–
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]

0.59% less ownership

Funds ownership: 78.77% [Q4 2024] → 78.18% (-0.59%) [Q1 2025]

13% less funds holding

Funds holding: 53 [Q4 2024] → 46 (-7) [Q1 2025]

19% less capital invested

Capital invested by funds: $52M [Q4 2024] → $41.9M (-$10.1M) [Q1 2025]

65% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 20

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for IMA.

See Analyst Rankings

Financial journalist opinion

Neutral
GlobeNewsWire
5 days ago
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflammatory (“I&I”) diseases, today announced the completion of its previously announced merger with Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”). The combined company will operate under the name ImageneBio, Inc. (“ImageneBio”) and will trade on The Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “IMA” beginning at market open on July 28, 2025.
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
See News Rankings
Charts implemented using Lightweight Charts™